-
公开(公告)号:US11117884B2
公开(公告)日:2021-09-14
申请号:US16664621
申请日:2019-10-25
发明人: Steven L. Wagner , William C. Mobley , Rudolph E. Tanzi , Graham Johnson , Ronald Buckle , Nicholas Mayhew , Robert Jason Herr , Kevin D. Rynearson
IPC分类号: C07D401/14 , C07D413/14 , C07D487/04 , A61P25/28
摘要: Provided herein are compounds and methods for treating a disorder associated with aberrant Aβ peptide levels, including Alzheimer's disease.
-
公开(公告)号:US09938263B2
公开(公告)日:2018-04-10
申请号:US14775483
申请日:2014-03-12
申请人: The Regents of the University of California, A California Corporation , The General Hospital Corporation
IPC分类号: C07D417/14 , C07D487/04
CPC分类号: C07D417/14 , C07D487/04
摘要: There are provided, inner alia, compounds and methods for lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase. Since all of the major AB peptide variants, including the pathogenic AB42 as known in the art, are ultimately generated by gamma-secretase-mediated proteolysis of APP-C99 (i.e., the beta-secretase-mediated cleavage product of the amyloid protein precursor IAPPI), one approach to therapeutic intervention (e.g., intervention in Alzheimer's Disease, AD) relates to lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase.
-
公开(公告)号:US20200055840A1
公开(公告)日:2020-02-20
申请号:US16664621
申请日:2019-10-25
发明人: Steven L. Wagner , William C. Mobley , Rudolph E. Tanzi , Graham Johnson , Ronald Buckle , Nicholas Mayhew , Robert Jason Herr , Kevin D. Rynearson
IPC分类号: C07D401/14 , A61P25/28 , C07D487/04 , C07D413/14
摘要: Provided herein are compounds and methods for treating a disorder associated with aberrant Aβ peptide levels, including Alzheimer's disease.
-
公开(公告)号:US10472346B2
公开(公告)日:2019-11-12
申请号:US15522969
申请日:2015-10-30
申请人: The General Hospital Coporation , The Regents of the University of California , Steven L. Wagner , William C. Mobley , Rudolph E. Tanzi , Graham Johnson , Ronald Buckle , Nicholas Mayhew , Robert Jason Herr
发明人: Steven L. Wagner , William C. Mobley , Rudolph E. Tanzi , Graham Johnson , Ronald Buckle , Nicholas Mayhew , Robert Jason Herr , Kevin D. Rynearson
IPC分类号: C07D401/14 , C07D413/14 , C07D487/04 , A61P25/28
摘要: Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant Aβ peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L′ is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.
-
公开(公告)号:US20180093967A1
公开(公告)日:2018-04-05
申请号:US15522969
申请日:2015-10-30
发明人: Steven L. Wagner , William C. Mobley , Rudolph E. Tanzi , Graham Johnson , Ronald Buckle , Nicholas Mayhew , Robert Jason Herr , Kevin D. Rynearson
IPC分类号: C07D401/14 , C07D413/14 , C07D487/04 , A61P25/28
摘要: Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant Aβ peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L′ is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.
-
-
-
-